CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
ZW25 (Zanidatamab) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04224272
NCT04224272Phase 2Completed
CompareCT.gov

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

Jazz Pharmaceuticals·interventional·Posted Jan 13, 2020·Updated Aug 1, 2025

In Brief

A Phase 2 clinical trial evaluating ZW25 (Zanidatamab), Palbociclib, and 1 other intervention for HER2+/HR+ Breast Cancer. Completed, enrolled 51 participants across 13 sites in 3 countries.

Detailed Summary

This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2+/HR+ Breast Cancer
CountriesCanada, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 13, 2020
Enrollment StartJun 10, 2020
Primary CompletionApr 28, 2023
Study CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.5 years ago

Interventions

ZW25 (Zanidatamab)drug

Administered intravenously

Palbociclibdrug

Administered orally

Fulvestrantdrug

Administered as an intramuscular injection